ReviewInfluenza and other respiratory viruses2015
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.
Review in Influenza and other respiratory viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.The Cochrane database of systematic reviews · 2023Pooled it
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.The Cochrane database of systematic reviews · 2019Pooled it
- Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.Influenza and other respiratory viruses · 2016Pooled it
- Genetic association of TLR4 Asp299Gly, TLR4 Thr399Ile, and CD14 C-159T polymorphisms with the risk of severe RSV infection: a meta-analysis.Influenza and other respiratory viruses · 2016Pooled it
- Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges.Frontiers in microbiology · 2026Review
- Management of a respiratory syncytial virus outbreak in a memory care unit at a long-term care facility.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Severe respiratory syncytial virus disease.Journal of intensive medicine · 2024Review
- Global progress in clinical research on human respiratory syncytial virus vaccines.Frontiers in microbiology · 2024Review
- Effects of pH alteration on respiratory syncytial virus in human airway epithelial cells.ERJ open research · 2023Article
- Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017.Influenza and other respiratory viruses · 2020Article
- Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.Antimicrobial agents and chemotherapy · 2020Article
- Progress in the development of virus-like particle vaccines against respiratory viruses.Expert review of vaccines · 2020Review
- [Respiratory syncytial virus].Der Internist · 2019Review
- Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children, Including Children Diagnosed with Asthma.Epidemiology (Cambridge, Mass.) · 2019Article
- Article
- Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.BMC pediatrics · 2019Observational
- Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17.Scientific reports · 2019Article
- Community-Acquired Pneumonia in Children: the Challenges of Microbiological Diagnosis.Journal of clinical microbiology · 2018Review
- Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Infectious diseases and therapy · 2018Review
- Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Viral immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.